{"success":true,"data":{"pressRelease":{"id":"166350","rtpr_id":"nGNX9T5ynF-20261012","ticker":"NXTS","exchange":"NASDAQ","all_tickers":["NXTS"],"title":"Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis","author":"Globe Newswire","published_at":"2026-10-12T12:07:00.101Z","article_body":"MitoCareX expands its internal bioinformatics expertise to broaden the\nanalysis of disease biology within its computational drug-discovery activities\n\nNess Ziona, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies\nInc.\n(https://www.globenewswire.com/Tracker?data=X5wRWX2RIDkYqAwZ_hRRo9361Wc6bRpk7DWfPf77430qsz8hw6mKag3kwvvVy0F0MuJepyzhpGXrheyi-pSw-6ADYYQkmqNQkZjXv2Rw-vk=)\n(NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that\nMitoCareX Bio Ltd. (“MitoCareX”), its wholly owned subsidiary, is\nbroadening its existing bioinformatics capabilities to include a greater focus\non the analysis of disease-relevant biological pathways within its\ncomputational drug-discovery platform.\n\nAs part of this initiative, MitoCareX has added an expert bioinformatician to\nits scientific team. Preliminary analyses generated by the Company are\ninforming the platform’s continued development.\n\nThe initiative is intended to broaden MitoCareX’s existing bioinformatics\nactivities and add a more structured, disease-focused analytical layer to its\ncomputational drug-discovery platform. While the platform’s established\ncapabilities have focused substantially on protein structure, molecular\ninteractions and structure-guided drug discovery, the developing\nbioinformatics capabilities are intended to provide additional context\nregarding how potential targets may relate to disease-associated biological\npathways.\n\nMitoCareX plans to incorporate the developing bioinformatics capabilities into\nits computational drug-discovery platform, complementing MITOLINE(®)-enabled\nstructural modeling, computational chemistry, virtual screening and\nspecialized biological research systems. This combined approach is intended to\nenable potential discovery opportunities to be evaluated from multiple\nperspectives, including their structural characteristics, potential molecular\ninteractions and relevance within the broader biology of disease.\n\nBy incorporating disease-related biological context earlier in the discovery\nprocess, MitoCareX intends for these bioinformatics capabilities to support\nthe evaluation of potential targets and research programs before they advance\ninto resource-intensive discovery activities. Over time, the Company expects\nthe expanded capabilities to broaden the range of scientific questions\naddressed by MitoCareX’s computational drug-discovery platform as it\nconsiders future discovery opportunities. These anticipated benefits remain\nsubject to the continued development, implementation and evaluation of the\nbioinformatics capabilities and supporting workflows.\n\n“Expanding our internal bioinformatics expertise represents a deliberate\nstep in broadening the scientific foundation of MitoCareX’s computational\ndrug-discovery platform,” said David Palach, Chief Executive Officer of\nNexentis Technologies Inc. “Our established capabilities enable us to\nexamine protein structures and potential molecular interactions. The broader\nbioinformatics capabilities now being developed are intended to add another\nimportant perspective by placing potential targets within the context of\ndisease-relevant biological pathways. We believe that bringing disease-biology\ninsights together with structural and molecular analysis may strengthen the\nbasis on which future discovery opportunities are evaluated and\nprioritized.”\n\nMitoCareX intends to continue developing its bioinformatics capabilities and\nsupporting workflows while evaluating how insights generated through these\ncapabilities may inform target-assessment and program-prioritization\nactivities. The Company also plans to assess how this developing\ndisease-biology layer may complement its protein-focused research and\ndownstream structural biology, computational chemistry and experimental\nworkflows.\n\nAbout MitoCareX Bio Ltd.\nMitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc.,\nis advancing a focused drug-discovery platform designed to translate\nmultidisciplinary scientific capabilities into potential therapeutic\ncandidates. By integrating biology, chemistry and computationally enabled\nresearch, MitoCareX supports ongoing research activities directed toward\ncandidate identification and development within its drug-discovery efforts.\nhttps://mitocarexbio.com/\n\nAbout Nexentis Technologies Inc.\nNexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd\n(https://www.globenewswire.com/Tracker?data=WPAGeUXwoRG1qZKUPy0WqgWEh8q02gm3Hh7aaaUora_ACGsjRwVFGF5hj2lYIQawkTt67Xosmsnraav-IY7PpaE_yC5mf3rnhLPLnapO4KzHRPcEEarH2HzCoxD4A85PkdAjvxmt-b1YoW_XuIt7gpW5OooVExbh4XBRdiwo3BSwoQ_aSBk6JbcaRiE8s2GXoVU1Hp7BqrT1yKKuhkegXWrHHfO3tp-_cHVmfpzMDO982_jl7Rf6iuEUgxZhgqiIvCDCHGNyQ0mZeCxYRd8UrV6MQij1GmQCFqZAq2DL3rGm40GiVzJuIa8olfgWF_VGWr3QTFzbdvEIWP8ODTqRUVXUekpslrRnkRXEm9X28epsS-ROGJ5acogjbgnUUk5isl0vC31dhP8ojNv6hDlV8lMwV4zKkPT4mC39vJ5omQeUwftQmj-lmD9mQBuGf8yZ),\na drug discovery company. Additionally, Nexentis adopted an investment\nstrategy focused on European renewable energy assets utilizing\na RTB (Ready to Build)\n(https://www.globenewswire.com/Tracker?data=YPmGpsMVtbHZhVMJTowr0DV2RdLavdg3S2-TsYSc9gOQubOUzzN8WCOZJsE3l63f5_J8jZkl78Ki6DQsxa2fZIieGFt8oASllR3xeFgfc4SR2PkZB_lXg0jDCh0pCWTD9NSG5e1Vd6CvpS02IBEGzJW5upjFa3oLKEhiAW5gulJ8aH7wVnUoRfSGLxRC3aIr1WvrYSYItYBu5tvt7pR5nhxp0qOH1oCw3QBloUxiFkOcxYEridiB_m2xQTv9lY9Zr_-wVJyPYAX0l-5zsaSKg-AtAjDcnrOiFCwbgK1nEKThLSedtpIEZXA1SN3qOLsCXEEwuDSRzrHPF2kPv3HIEGV7VmZXHleRzn6dwy6GVs9VZD7hxFdia34qtv-OrT4V0qZcSyapuZhgXX6OsgblTjO9yLMKT3bs0H5KeHyZvP6sGNEWBxBJLPmsRebHLRCuDiUWPROw08vR5Pq1JqPvzfLtFWyyHDY4uHCo5-2Wwarec9SnPKErIywiAMQzmamnL3P-Cg4NuZNjpUugwLJCn-iJAV13ZiNc93ef408FDPQ=) business\nmodel. The Company is currently the lead investor in four solar projects\nacross three European Union countries, all introduced by Solterra Renewable\nEnergy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.\n\nFor additional details, please visit https://nexentistech.com/\n\nForward-looking Statements:\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995 and other Federal securities laws. Words such as “expects,”\n“anticipates,” “intends,” “plans,” “believes,” “seeks,”\n“estimates” and similar expressions or variations of such words are\nintended to identify forward-looking statements. For example, the Company is\nusing forward-looking statements when it discusses the continued development,\nimplementation and integration of MitoCareX’s bioinformatics capabilities\nand supporting workflows; the potential incorporation of disease-pathway\nanalysis into MitoCareX’s computational drug-discovery platform; the\nanticipated ability of these capabilities to provide additional\ndisease-related biological context, support the evaluation and prioritization\nof potential targets and research programs, and complement MitoCareX’s\nexisting structural biology, computational chemistry, virtual-screening and\nexperimental workflows; and the potential expansion of the scientific\nquestions and future discovery opportunities addressed by MitoCareX’s\nplatform. Because forward-looking statements relate to matters that have not\nyet occurred, these statements are inherently subject to known and unknown\nrisks, uncertainties and other factors that may cause the Company’s and its\nsubsidiaries’ actual results, performance or achievements to be materially\ndifferent from any future results, performance or achievements expressed or\nimplied by the forward-looking statements. Important factors that could cause\nactual results, performance or achievements to differ materially from those\nanticipated in these forward-looking statements include, among other things,\nour market and other conditions, history of losses and needs for additional\ncapital to fund our operations and our inability to obtain additional capital\non acceptable terms, or at all; uncertainties of cash flows and inability to\nmeet working capital needs; the initiation, timing, progress and results of\nour preclinical studies, clinical trials and other product candidate\ndevelopment efforts; our ability to advance our product candidates into\nclinical trials or to successfully complete our preclinical studies or\nclinical trials; our receipt of regulatory approvals for our product\ncandidates, and the timing of other regulatory filings and approvals; the\nclinical development, commercialization and market acceptance of our product\ncandidates; our ability to establish and maintain strategic partnerships and\nother corporate collaborations; the implementation of our business model and\nstrategic plans for our business and product candidates; the scope of\nprotection we are able to establish and maintain for intellectual property\nrights covering our product candidates and our ability to operate our business\nwithout infringing the intellectual property rights of others; competitive\ncompanies, technologies and our industry; risks related to not satisfying the\ncontinued listing requirements of Nasdaq Capital Market; and statements as to\nthe impact of the political and security situation in Israel on our business.\nMore information on these risks, uncertainties and other factors is included\nfrom time to time in the “Risk Factors” section of the Company’s Annual\nReport on Form 10-K filed with the Securities and Exchange Commission\n(“SEC”) on March 31, 2026 and other public reports filed with the SEC.\nExcept as otherwise required by law, we undertake no obligation to publicly\nrelease any revisions to these forward-looking statements to reflect events or\ncircumstances after the date hereof or to reflect the occurrence of\nunanticipated events. References and links to websites have been provided as a\nconvenience, and the information contained on such websites is not\nincorporated by reference into this press release. We are not responsible for\nthe contents of third-party websites.\n\nInvestor Relations Contact:\nMichal Efraty\nmichal@efraty.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0e0c11bd-6abb-4596-afc6-7033325e5030)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9T5ynF-20261012","title":"Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis","author":"Globe Newswire","ticker":"NXTS","created":"2026-10-12T12:07:00.101Z","tickers":["NXTS"],"exchange":"NASDAQ","article_body":"MitoCareX expands its internal bioinformatics expertise to broaden the\nanalysis of disease biology within its computational drug-discovery activities\n\nNess Ziona, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies\nInc.\n(https://www.globenewswire.com/Tracker?data=X5wRWX2RIDkYqAwZ_hRRo9361Wc6bRpk7DWfPf77430qsz8hw6mKag3kwvvVy0F0MuJepyzhpGXrheyi-pSw-6ADYYQkmqNQkZjXv2Rw-vk=)\n(NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that\nMitoCareX Bio Ltd. (“MitoCareX”), its wholly owned subsidiary, is\nbroadening its existing bioinformatics capabilities to include a greater focus\non the analysis of disease-relevant biological pathways within its\ncomputational drug-discovery platform.\n\nAs part of this initiative, MitoCareX has added an expert bioinformatician to\nits scientific team. Preliminary analyses generated by the Company are\ninforming the platform’s continued development.\n\nThe initiative is intended to broaden MitoCareX’s existing bioinformatics\nactivities and add a more structured, disease-focused analytical layer to its\ncomputational drug-discovery platform. While the platform’s established\ncapabilities have focused substantially on protein structure, molecular\ninteractions and structure-guided drug discovery, the developing\nbioinformatics capabilities are intended to provide additional context\nregarding how potential targets may relate to disease-associated biological\npathways.\n\nMitoCareX plans to incorporate the developing bioinformatics capabilities into\nits computational drug-discovery platform, complementing MITOLINE(®)-enabled\nstructural modeling, computational chemistry, virtual screening and\nspecialized biological research systems. This combined approach is intended to\nenable potential discovery opportunities to be evaluated from multiple\nperspectives, including their structural characteristics, potential molecular\ninteractions and relevance within the broader biology of disease.\n\nBy incorporating disease-related biological context earlier in the discovery\nprocess, MitoCareX intends for these bioinformatics capabilities to support\nthe evaluation of potential targets and research programs before they advance\ninto resource-intensive discovery activities. Over time, the Company expects\nthe expanded capabilities to broaden the range of scientific questions\naddressed by MitoCareX’s computational drug-discovery platform as it\nconsiders future discovery opportunities. These anticipated benefits remain\nsubject to the continued development, implementation and evaluation of the\nbioinformatics capabilities and supporting workflows.\n\n“Expanding our internal bioinformatics expertise represents a deliberate\nstep in broadening the scientific foundation of MitoCareX’s computational\ndrug-discovery platform,” said David Palach, Chief Executive Officer of\nNexentis Technologies Inc. “Our established capabilities enable us to\nexamine protein structures and potential molecular interactions. The broader\nbioinformatics capabilities now being developed are intended to add another\nimportant perspective by placing potential targets within the context of\ndisease-relevant biological pathways. We believe that bringing disease-biology\ninsights together with structural and molecular analysis may strengthen the\nbasis on which future discovery opportunities are evaluated and\nprioritized.”\n\nMitoCareX intends to continue developing its bioinformatics capabilities and\nsupporting workflows while evaluating how insights generated through these\ncapabilities may inform target-assessment and program-prioritization\nactivities. The Company also plans to assess how this developing\ndisease-biology layer may complement its protein-focused research and\ndownstream structural biology, computational chemistry and experimental\nworkflows.\n\nAbout MitoCareX Bio Ltd.\nMitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc.,\nis advancing a focused drug-discovery platform designed to translate\nmultidisciplinary scientific capabilities into potential therapeutic\ncandidates. By integrating biology, chemistry and computationally enabled\nresearch, MitoCareX supports ongoing research activities directed toward\ncandidate identification and development within its drug-discovery efforts.\nhttps://mitocarexbio.com/\n\nAbout Nexentis Technologies Inc.\nNexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd\n(https://www.globenewswire.com/Tracker?data=WPAGeUXwoRG1qZKUPy0WqgWEh8q02gm3Hh7aaaUora_ACGsjRwVFGF5hj2lYIQawkTt67Xosmsnraav-IY7PpaE_yC5mf3rnhLPLnapO4KzHRPcEEarH2HzCoxD4A85PkdAjvxmt-b1YoW_XuIt7gpW5OooVExbh4XBRdiwo3BSwoQ_aSBk6JbcaRiE8s2GXoVU1Hp7BqrT1yKKuhkegXWrHHfO3tp-_cHVmfpzMDO982_jl7Rf6iuEUgxZhgqiIvCDCHGNyQ0mZeCxYRd8UrV6MQij1GmQCFqZAq2DL3rGm40GiVzJuIa8olfgWF_VGWr3QTFzbdvEIWP8ODTqRUVXUekpslrRnkRXEm9X28epsS-ROGJ5acogjbgnUUk5isl0vC31dhP8ojNv6hDlV8lMwV4zKkPT4mC39vJ5omQeUwftQmj-lmD9mQBuGf8yZ),\na drug discovery company. Additionally, Nexentis adopted an investment\nstrategy focused on European renewable energy assets utilizing\na RTB (Ready to Build)\n(https://www.globenewswire.com/Tracker?data=YPmGpsMVtbHZhVMJTowr0DV2RdLavdg3S2-TsYSc9gOQubOUzzN8WCOZJsE3l63f5_J8jZkl78Ki6DQsxa2fZIieGFt8oASllR3xeFgfc4SR2PkZB_lXg0jDCh0pCWTD9NSG5e1Vd6CvpS02IBEGzJW5upjFa3oLKEhiAW5gulJ8aH7wVnUoRfSGLxRC3aIr1WvrYSYItYBu5tvt7pR5nhxp0qOH1oCw3QBloUxiFkOcxYEridiB_m2xQTv9lY9Zr_-wVJyPYAX0l-5zsaSKg-AtAjDcnrOiFCwbgK1nEKThLSedtpIEZXA1SN3qOLsCXEEwuDSRzrHPF2kPv3HIEGV7VmZXHleRzn6dwy6GVs9VZD7hxFdia34qtv-OrT4V0qZcSyapuZhgXX6OsgblTjO9yLMKT3bs0H5KeHyZvP6sGNEWBxBJLPmsRebHLRCuDiUWPROw08vR5Pq1JqPvzfLtFWyyHDY4uHCo5-2Wwarec9SnPKErIywiAMQzmamnL3P-Cg4NuZNjpUugwLJCn-iJAV13ZiNc93ef408FDPQ=) business\nmodel. The Company is currently the lead investor in four solar projects\nacross three European Union countries, all introduced by Solterra Renewable\nEnergy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.\n\nFor additional details, please visit https://nexentistech.com/\n\nForward-looking Statements:\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995 and other Federal securities laws. Words such as “expects,”\n“anticipates,” “intends,” “plans,” “believes,” “seeks,”\n“estimates” and similar expressions or variations of such words are\nintended to identify forward-looking statements. For example, the Company is\nusing forward-looking statements when it discusses the continued development,\nimplementation and integration of MitoCareX’s bioinformatics capabilities\nand supporting workflows; the potential incorporation of disease-pathway\nanalysis into MitoCareX’s computational drug-discovery platform; the\nanticipated ability of these capabilities to provide additional\ndisease-related biological context, support the evaluation and prioritization\nof potential targets and research programs, and complement MitoCareX’s\nexisting structural biology, computational chemistry, virtual-screening and\nexperimental workflows; and the potential expansion of the scientific\nquestions and future discovery opportunities addressed by MitoCareX’s\nplatform. Because forward-looking statements relate to matters that have not\nyet occurred, these statements are inherently subject to known and unknown\nrisks, uncertainties and other factors that may cause the Company’s and its\nsubsidiaries’ actual results, performance or achievements to be materially\ndifferent from any future results, performance or achievements expressed or\nimplied by the forward-looking statements. Important factors that could cause\nactual results, performance or achievements to differ materially from those\nanticipated in these forward-looking statements include, among other things,\nour market and other conditions, history of losses and needs for additional\ncapital to fund our operations and our inability to obtain additional capital\non acceptable terms, or at all; uncertainties of cash flows and inability to\nmeet working capital needs; the initiation, timing, progress and results of\nour preclinical studies, clinical trials and other product candidate\ndevelopment efforts; our ability to advance our product candidates into\nclinical trials or to successfully complete our preclinical studies or\nclinical trials; our receipt of regulatory approvals for our product\ncandidates, and the timing of other regulatory filings and approvals; the\nclinical development, commercialization and market acceptance of our product\ncandidates; our ability to establish and maintain strategic partnerships and\nother corporate collaborations; the implementation of our business model and\nstrategic plans for our business and product candidates; the scope of\nprotection we are able to establish and maintain for intellectual property\nrights covering our product candidates and our ability to operate our business\nwithout infringing the intellectual property rights of others; competitive\ncompanies, technologies and our industry; risks related to not satisfying the\ncontinued listing requirements of Nasdaq Capital Market; and statements as to\nthe impact of the political and security situation in Israel on our business.\nMore information on these risks, uncertainties and other factors is included\nfrom time to time in the “Risk Factors” section of the Company’s Annual\nReport on Form 10-K filed with the Securities and Exchange Commission\n(“SEC”) on March 31, 2026 and other public reports filed with the SEC.\nExcept as otherwise required by law, we undertake no obligation to publicly\nrelease any revisions to these forward-looking statements to reflect events or\ncircumstances after the date hereof or to reflect the occurrence of\nunanticipated events. References and links to websites have been provided as a\nconvenience, and the information contained on such websites is not\nincorporated by reference into this press release. We are not responsible for\nthe contents of third-party websites.\n\nInvestor Relations Contact:\nMichal Efraty\nmichal@efraty.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0e0c11bd-6abb-4596-afc6-7033325e5030)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-12T12:07:00.13861169Z","server_sent_at_ms":1791806820138},"received_at":"2026-10-12T12:07:00.189Z","source_url":null},"analysis":{"id":"154710","press_release_id":"166350","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["company discloses history of losses and need for additional capital in risk factors","risk of not satisfying Nasdaq continued listing requirements noted"],"eventType":"operations_update","narrative":"Nexentis' subsidiary MitoCareX Bio is broadening its bioinformatics capabilities to add disease-pathway analysis to its computational drug-discovery platform, hiring an expert bioinformatician as part of the initiative.\n\nThe new disease-biology layer is intended to complement MITOLINE-enabled structural modeling, computational chemistry and virtual screening, helping prioritize targets before resource-intensive discovery work begins.\n\nThe announcement contains no financial figures or clinical milestones, and the anticipated benefits remain subject to continued development and evaluation — a modest scientific-capability update rather than a material event.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine R&D capability expansion at subsidiary — low-signal; suppress unless tracking NXTS drug-discovery pipeline."},"keyFigures":{},"quotedText":"Expanding our internal bioinformatics expertise represents a deliberate step in broadening the scientific foundation of MitoCareX's computational drug-discovery platform","namedEntities":{"people":[{"name":"David Palach","role":"CEO of Nexentis Technologies Inc."},{"name":"Michal Efraty","role":"Investor Relations contact"}],"products":["MITOLINE"],"companies":[{"name":"Nexentis Technologies Inc.","ticker":"NXTS","relationship":"filer/parent"},{"name":"MitoCareX Bio Ltd.","relationship":"wholly owned subsidiary"},{"name":"Solterra Renewable Energy Ltd.","relationship":"project introducer for solar investments"},{"name":"Solterra Energy Ltd.","relationship":"parent of Solterra Renewable Energy"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine capability-expansion announcement: a subsidiary added one bioinformatician and is developing disease-pathway analysis. No financial figures, clinical results, or near-term revenue impact disclosed."},"tickerRelevance":{"others":[],"primary":"NXTS"},"globalImportance":10,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"routine capability expansion, no financial figures","issuerAuthored":true,"retailFavoriteBoost":false}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Nexentis' subsidiary MitoCareX Bio is broadening its bioinformatics capabilities to add disease-pathway analysis to its computational drug-discovery platform, hiring an expert bioinformatician as part of the initiative.\n\nThe new disease-biology layer is intended to complement MITOLINE-enabled structural modeling, computational chemistry and virtual screening, helping prioritize targets before resource-intensive discovery work begins.\n\nThe announcement contains no financial figures or clinical milestones, and the anticipated benefits remain subject to continued development and evaluation — a modest scientific-capability update rather than a material event.","key_figures":{},"named_entities":{"people":[{"name":"David Palach","role":"CEO of Nexentis Technologies Inc."},{"name":"Michal Efraty","role":"Investor Relations contact"}],"products":["MITOLINE"],"companies":[{"name":"Nexentis Technologies Inc.","ticker":"NXTS","relationship":"filer/parent"},{"name":"MitoCareX Bio Ltd.","relationship":"wholly owned subsidiary"},{"name":"Solterra Renewable Energy Ltd.","relationship":"project introducer for solar investments"},{"name":"Solterra Energy Ltd.","relationship":"parent of Solterra Renewable Energy"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-12T12:07:05.168Z","global_importance":10,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"routine capability expansion, no financial figures","issuerAuthored":true,"retailFavoriteBoost":false}},"durationMs":4959,"modelName":"glm-5.3-flashx"}}